周三，诺和诺德(NVO.US)股价走低，截至发稿，该股跌超5%，报51.08美元。昨日该公司发布严重盈利 预警，预计2025年营收和利润将双双下滑，股价收跌超21%。过去一年，诺和诺德股价已累计暴跌逾 58%。 （文章来源：智通财经） ...

Core Viewpoint - Novo Nordisk (NVO.US) shares fell over 5% to $51.08 following a severe profit warning, with expectations of revenue and profit declines in 2025, leading to a more than 21% drop in stock price the previous day. The stock has plummeted over 58% in the past year [1]. Financial Performance - The company issued a significant profit warning, projecting declines in both revenue and profit for 2025 [1]. - The stock price experienced a sharp decline of over 21% after the announcement of the profit warning [1]. - Over the past year, Novo Nordisk's stock has decreased by more than 58% [1].

周三，诺和诺德(NVO.US)股价走低，截至发稿，该股跌超5%，报51.08美元。昨日该公司发布严重盈利 预警，预计2025年营收和利润将双双下滑，股价收跌超21%。过去一年，诺和诺德股价已累计暴跌逾 58%。 ...

Group 1 - U.S. stock indices opened slightly higher, with Dow Jones up 0.05%, Nasdaq up 0.19%, and S&P 500 up 0.11% [1] - New Oriental's net profit for Q4 FY2025 decreased by 73.7% year-on-year, leading to a drop of over 10% in its stock price [1] - Starbucks saw a stock increase of over 5% after reporting third-quarter revenue that exceeded expectations [1] Group 2 - Novo Nordisk's stock fell over 5% in pre-market trading after a significant drop of 21% the previous day, as new CEO Lars Fruergaard Jørgensen failed to reassure investors [2] - Apple has lost four AI researchers to Meta in a month, with the latest departure being multimodal AI researcher Bowen Zhang [2] Group 3 - LG Energy Solution secured a supply contract for lithium iron phosphate (LFP) batteries worth 5.9442 trillion KRW (approximately $4.3 billion), which represents 23.2% of its projected 2024 sales [3] - The customer behind the $4.3 billion contract is reportedly Tesla, although LG did not disclose the client's identity [3] Group 4 - Starbucks reported its first same-store sales growth in China in a year and a half, despite a global decline in same-store sales for six consecutive quarters [4]

Group 1 - Novo Nordisk's stock price has been declining significantly after issuing a profit warning and appointing a new CEO, resulting in a market value loss of $70 billion [2] - The company has lowered its sales growth forecast for 2025 from 13%-21% to 8%-14%, and its operating profit growth forecast from 16%-24% to 10%-16% [2] - Since the launch of Wegovy in 2021, Novo Nordisk's market value peaked at $615 billion but has since dropped by two-thirds due to concerns over losing competitive advantage in the weight loss drug market [2] Group 2 - The stock experienced a sharp decline of 23% on Tuesday, with an intraday drop of 30% [3] - The sales forecast downgrade is attributed to competition from compounded generic drugs that use the same active ingredients as the branded drug, which caught investors off guard [3] - Barclays downgraded Novo Nordisk's rating from "Overweight" to "Neutral," citing a significant credibility crisis regarding the company's assessment of its issues [3] Group 3 - Novo Nordisk is intensifying efforts to regain patients using compounded generics and has increased dialogue with the FDA to curb illegal compounded drugs [3] - JPMorgan maintained an "Overweight" rating but reduced the target price from 650 to 500 Danish kroner, indicating cautious optimism about a potential recovery in U.S. prescriptions [3]

I'm passionate about finance and investing, focusing on business analysis, fundamental analysis, valuation, and long-term growth, especially in sectors like AI, fintech, finance and tech. I study finance and economy and have hands-on experience in equity research, financial modeling, and creating investment content. I actively analyze publicly traded companies with a focus on business models, earnings performance, and competitive positioning. I also run a finance-focused YouTube channel called "The Market M ...

Group 1 - Novo Nordisk's stock price has been declining following a profit warning and the appointment of a new CEO, resulting in a market value loss of $70 billion [1] - The company has significantly lowered its sales growth forecast for 2025, now expecting an 8%-14% increase in sales, down from a previous estimate of 13%-21% [1] - Novo Nordisk's operating profit growth forecast has also been reduced from 16%-24% to 10%-16% [1] Group 2 - The sales forecast downgrade is attributed to competition from compounded generic drugs that use the same active ingredients as the branded drug Wegovy [2] - The incoming CEO, Maziar Mike Doustdar, claimed that Wegovy's growth momentum is still strong, but the management failed to alleviate market concerns during a call with investors [2] - Barclays downgraded Novo Nordisk's rating from "overweight" to "neutral," citing a significant credibility crisis regarding the company's assessment of its issues [2]

Analyst's Disclosure:I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any inv ...

格隆汇7月30日｜美国银行将诺和诺德评级从买入下调至中性，将目标价从550丹麦克朗下调至375丹麦 克朗。 ...

美国银行：将诺和诺德评级从买入下调至中性；将目标价从550丹麦克朗下调至375丹麦克朗。 ...